Clinical Trial Update: Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer [NA]

View source ↗

Summary

A completed study by Delfi Diagnostics evaluated the real-world clinical utility of fragmentomics-based screening for individuals at elevated risk for lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Snippet

Sponsor: Delfi Diagnostics Inc. | Conditions: Lung Cancer | NA | Status: COMPLETED